May 11, 2023 Up to 40% could be slashed from projected global gene-therapy sales if companies follow Bluebird by exiting Europe amid reimbursement stalemates. Previous Post Taiwans Wind Industry Braves CrossStrait Risks in Clean Energy Boom Next Post Loan officer survey points to weaker lending amid banking unease
